已收盘 03-27 16:00:00 美东时间
-0.110
-0.72%
今日重点评级关注:HC Wainwright & Co.:维持Perspective Therapeutics"买入"评级,目标价从12美元升至13美元;Litchfield Hills:维持Star Equity Holdings"买入"评级,目标价从21美元升至28美元
03-24 10:07
今日重点评级关注:瑞穗:维持RELMADA THERAPEUTICS"跑赢大市"评级,目标价从10美元升至19美元;奥本海默:维持Pelthos Therapeutics"跑赢大市"评级,目标价从60美元升至62美元
03-23 13:53
BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.
03-20 18:20
Theravance Biopharma press release (TBPH): Q4 net income was $61.0 million. Revenue of $45.9 million. Cash, cash equivalents and marketable securities totaled $326.5 million as of December 31, 2025. M...
03-20 02:54
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.02 by 12.75 percent. This is a 2400 percent increase over losses of $(0.05) per share from
03-19 20:37
Theravance Biopharma Q4 net income hits USD 61.02 million as total revenue rises 145% to USD 45.89 million Theravance published a press release reporting Q4 and full-year 2025 results, including Q4 total revenue of USD 45.89 million and Q4 net income of USD 61.02 million. Viatris collaboration reven
03-19 20:32
Oppenheimer analyst Trevor Allred downgrades Theravance Biopharma (NASDAQ:TBPH) from Outperform to Perform.
03-06 01:59
今日重点评级关注:古根海姆:维持Dianthus Therapeutics"买入"评级,目标价从100美元升至200美元;HC Wainwright & Co.:维持Amylyx Pharmaceuticals"买入"评级,目标价从28美元升至34美元
03-05 13:56
Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
03-04 20:35
今日重点评级关注:HC Wainwright & Co.:维持NRX Pharmaceuticals"买入"评级,目标价从40美元升至45美元;RBC Capital:维持NUVATION BIO"跑赢大市"评级,目标价从12美元升至13美元
03-04 10:22